Endothelial dysfunction biomarker, endothelial cell-specific molecule-1, and pediatric metabolic syndrome

Pediatr Int. 2016 Nov;58(11):1124-1129. doi: 10.1111/ped.12989. Epub 2016 Jun 21.

Abstract

Background: The aim of this study was to compare serum endothelial cell-specific molecule-1 (endocan) in pediatric patients with metabolic syndrome (MetS) and in healthy children, and to determine whether it can be used as an indicator of endothelium damage-induced complications in pediatric MetS patients.

Methods: The study included 30 patients, aged 6-16 years, who were diagnosed with MetS. Another 30 children with no diseases were recruited as healthy controls. Endocan concentration was measured using enzyme-linked immunosorbent assay.

Results: Endocan was increased almost threefold in the MetS group compared with the healthy group. Systolic arterial tension and diastolic arterial tension, serum triglyceride, total cholesterol, and low-density lipoprotein cholesterol were higher, and high-density lipoprotein cholesterol was lower, in the MetS children than in the healthy group. Fasting blood glucose (FBG), hemoglobin A1c (HBA1C), and homeostasis model assessment insulin resistance (HOMA-IR) were also significantly increased in the children with MetS compared with the healthy group.

Conclusions: Serum endocan level in pediatric MetS patients could be an important indicator of cardiovascular risk in adulthood.

Keywords: endocan; endothelial dysfunction; enzyme-linked immunosorbent assay; metabolic syndrome; pediatric.

MeSH terms

  • Adolescent
  • Biomarkers / blood
  • Child
  • Endothelium, Vascular / physiopathology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Humans
  • Male
  • Metabolic Syndrome / blood*
  • Metabolic Syndrome / physiopathology
  • Neoplasm Proteins / metabolism*
  • Proteoglycans / metabolism*
  • Retrospective Studies
  • Vasodilation / physiology*

Substances

  • Biomarkers
  • ESM1 protein, human
  • Neoplasm Proteins
  • Proteoglycans